NCT02219685View on ClinicalTrials.gov

Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

April 30, 2016

Conditions
Hepatitis C Virus Infection
Interventions
DRUG

LDV/SOF

90/400 mg FDC tablet administered orally once daily

DRUG

Placebo

Tablet administered orally once daily

Trial Locations (1)

Unknown

Boston

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT02219685 - Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection | Biotech Hunter | Biotech Hunter